ANXA5 and myocardial infarction: Therapeutic options could include inhibiting CMV release after myocardial infarction using low doses of the Ca2+-Channel inhibitor Verapamil [42], inhibiting MV uptake by target cells using Annexin V [43] or by inhibiting specific miRNAs using specialized antagomirs [44].